Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 6/20 | 1.00 |
| ▸ | DPP4 | P27487 | 6/20 | 1.00 |
| ▸ | ESR1 | P03372 | 10/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10907340 | 0.92 | ANPEP (0.84) | ANPEPDPP4ESR1NR1H2NR1H3 | |
| SCHEMBL13171786 | 0.83 | ANPEP (0.71) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL29366407 | 0.82 | DPP4 (0.78) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL2820118 | 0.82 | DPP4 (0.78) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL2818285 | 0.82 | ANPEP (1.00) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL9812636 | 0.82 | ANPEP (0.69) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL29936544 | 0.81 | ANPEP (0.68) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL30278883 | 0.81 | ANPEP (0.68) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL30954668 | 0.80 | ANPEP (0.67) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL17531021 | 0.80 | ANPEP (0.67) | ANPEPDPP4NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240124523-A1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-18 | — | — | US | disclosed |
| US-20240091387-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| CN-111246873-B | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnosis and therapy delivery | 加利福尼亚大学董事会 | 2024-03-01 | — | — | CN | disclosed |
| US-11802138-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230099031-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20080306134-A1 | THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES | CHARLESSON, LLC | 2008-12-11 | — | — | US | disclosed |
| US-20080306134-A1 | THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES | CHARLESSON, LLC | 2008-12-11 | — | — | US | disclosed |
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | BRIGHAM AND WOMEN"S HOSPITAL (US) | 2005-03-31 | — | — | US | disclosed |
| EP-1487471-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS AND REAGENTS RELATED THERETO | Trustees of Tufts College (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003045228-A9 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TUFTS COLLEGE (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2003045228-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | ANPEP 2602/4885DPP4 3841/4885ESR1 4379/4885 |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | SLC2A8, VEGFA, SLC2A1 | ANPEP 363/4885DPP4 35/4885ESR1 4269/4885 |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | ANPEP 3256/4885DPP4 3309/4885ESR1 3416/4885 |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | CRBN, STUB1, ADRM1 | ANPEP 2096/4885DPP4 3175/4885ESR1 1251/4885 |
| US-20080306134-A1 | THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES | VEGFA, FLT1, VCAM1 | ANPEP 3507/4885DPP4 4355/4885ESR1 4688/4885 |
| US-20230099031-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | MDM2, SUMO2, MYCBP2 | ANPEP 2352/4885DPP4 3704/4885ESR1 2605/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | ANPEP 95/4885DPP4 869/4885ESR1 4701/4885 |
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | DNPEP, PREP, VIP | ANPEP 21/4885DPP4 11/4885ESR1 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.